Terns Pharmaceuticals, Inc. (TERN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.81 |
| Open | 5.72 |
| Bid | 5.74 x 800 |
| Ask | 7.50 x 800 |
| Day's Range | 5.59 - 6.13 |
| 52 Week Range | 5.43 - 28.36 |
| Volume | |
| Avg. Volume | 72,160 |
| Market Cap | 145.792M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.13 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Fair Value
Related Research
- Terns Pharmaceuticals, Inc.EXTR: Lowering target price to $14.00EXTREME NETWORKS INC has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat3 days agoArgus Research
- GlobeNewswire
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer
FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced the appointment of Jeffrey R. Jasper, Ph.D., as senior vice president, head of research. Dr. Jasper joins Terns with more than 28 years of experience in
- GlobeNewswire
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced that the Company’s management team will present at the following investor conferences in January: 40th Annual J.P. Morgan Health Care Conference Date: J
- GlobeNewswire
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
-Top-line data readout from TERN-201 (VAP-1) clinical trial in NASH expected in 1Q 2022 -Positive top-line data from TERN-501 (THR-β) demonstrated clinical proof of concept, enabling the planned initiation of NASH trial in 1H 2022 -Multiple abstracts detailing positive clinical data for TERN-101 and TERN-501 presented at AASLD 2021 -Cash and equivalents of $177 million provides runway into 2024 FOSTER CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Co
